Novartis to boost eye care portfolio with $3.4bn buy

10-05-2019

Novartis to boost eye care portfolio with $3.4bn buy

sruilk / Shutterstock.com

Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.


Novartis, Takeda, mergers and acquisitions, M&A, Xiidra, dry eye treatment, eye care portfolio,

LSIPR